Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis.

Staflin K, Krueger JS, Hachmann J, Forsyth JS, Lorger M, Steiniger SC, Mee J, Pop C, Salvesen GS, Janda KD, Felding-Habermann B.

Clin Exp Metastasis. 2010 Apr;27(4):217-31. doi: 10.1007/s10585-010-9320-5. Epub 2010 Mar 12.

2.

Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis.

Felding-Habermann B, Lerner RA, Lillo A, Zhuang S, Weber MR, Arrues S, Gao C, Mao S, Saven A, Janda KD.

Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17210-5. Epub 2004 Nov 24.

3.

Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream.

Weber MR, Zuka M, Lorger M, Tschan M, Torbett BE, Zijlstra A, Quigley JP, Staflin K, Eliceiri BP, Krueger JS, Marchese P, Ruggeri ZM, Felding BH.

Thromb Res. 2016 Apr;140 Suppl 1:S27-36. doi: 10.1016/S0049-3848(16)30095-0.

4.

Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.

Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS, Tice DA.

Mol Cancer Ther. 2006 Dec;5(12):3122-9.

5.

Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein.

Liu D, Wang C, Li C, Zhang X, Zhang B, Mi Z, An X, Tong Y.

J Biol Chem. 2011 Jul 8;286(27):24500-7. doi: 10.1074/jbc.M110.211847. Epub 2011 May 23.

6.

Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells.

Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9482-7. Epub 2003 Jul 21.

7.

Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.

Lorger M, Krueger JS, O'Neal M, Staflin K, Felding-Habermann B.

Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10666-71. doi: 10.1073/pnas.0903035106. Epub 2009 Jun 16.

8.

Targeting nuclear factor-κB suppresses the negative effect of toll-like receptor 4 signaling on antimetastasis therapy based on targeting αvβ3.

Zhu JH, Yuan Y, Li D, Liao SJ, Zhou YH, Wang Q, Shu Y, Yan B, Wei JJ, Sun R, Zhang GM, Feng ZH.

Cancer Sci. 2012 Jul;103(7):1319-26. doi: 10.1111/j.1349-7006.2012.02299.x. Epub 2012 May 15.

9.

The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle.

Xiao W, Wang Y, Lau EY, Luo J, Yao N, Shi C, Meza L, Tseng H, Maeda Y, Kumaresan P, Liu R, Lightstone FC, Takada Y, Lam KS.

Mol Cancer Ther. 2010 Oct;9(10):2714-23. doi: 10.1158/1535-7163.MCT-10-0308. Epub 2010 Sep 21.

10.

Ligands for mapping alphavbeta3-integrin expression in vivo.

Schottelius M, Laufer B, Kessler H, Wester HJ.

Acc Chem Res. 2009 Jul 21;42(7):969-80. doi: 10.1021/ar800243b.

PMID:
19489579
11.

Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.

Cai W, Chen X.

Anticancer Agents Med Chem. 2006 Sep;6(5):407-28. Review.

PMID:
17017851
12.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

13.

Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin.

Richards J, Miller M, Abend J, Koide A, Koide S, Dewhurst S.

J Mol Biol. 2003 Mar 7;326(5):1475-88.

PMID:
12595259
14.

Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells.

Duan X, Jia SF, Zhou Z, Langley RR, Bolontrade MF, Kleinerman ES.

Clin Exp Metastasis. 2004;21(8):747-53.

PMID:
16035619
15.

Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.

Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P, Clézardin P.

Cancer Res. 2007 Jun 15;67(12):5821-30.

16.

Role of α5β1 and αvβ3 integrins in relation to adhesion and spreading dynamics of prostate cancer cells interacting with fibronectin under in vitro conditions.

Stachurska A, Elbanowski J, Kowalczyńska HM.

Cell Biol Int. 2012 Oct 1;36(10):883-92. doi: 10.1042/CBI20110522.

PMID:
22686483
17.

RGD binding to integrin alphavbeta3 affects cell motility and adhesion in primary human breast cancer cultures.

Georgoulis A, Havaki S, Drosos Y, Goutas N, Vlachodimitropoulos D, Aleporou-Marinou V, Kittas C, Marinos E, Kouloukoussa M.

Ultrastruct Pathol. 2012 Dec;36(6):387-99. doi: 10.3109/01913123.2012.681834. Epub 2012 Nov 26.

PMID:
23181508
18.

ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.

Beck V, Herold H, Benge A, Luber B, Hutzler P, Tschesche H, Kessler H, Schmitt M, Geppert HG, Reuning U.

Int J Biochem Cell Biol. 2005 Mar;37(3):590-603.

PMID:
15618016
19.

Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells.

Cayrol F, Díaz Flaqué MC, Fernando T, Yang SN, Sterle HA, Bolontrade M, Amorós M, Isse B, Farías RN, Ahn H, Tian YF, Tabbò F, Singh A, Inghirami G, Cerchietti L, Cremaschi GA.

Blood. 2015 Jan 29;125(5):841-51. doi: 10.1182/blood-2014-07-587337. Epub 2014 Dec 8.

20.

Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone.

Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, Anderson RL.

Breast Cancer Res. 2006;8(2):R20. Epub 2006 Apr 11.

Supplemental Content

Support Center